Payment overview · 2025
General Payments
$439.41
6 reported records · 4 companies
Healthcare provider profile · identity verified
Khattar Aizooky, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PRESTO, PA · NPI 1750460614
Verified facts
What the public records show
CMS Open Payments records show Khattar Aizooky, M.D. received $439.41 in general payments during 2025 across 6 reported records.
Edwards Lifesciences Corporation accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $226.48 | 51.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 28.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.08 | 11.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.85 | 8.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.41 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $226.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.85 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 639 | 174 |
| Atorvastatin Calcium | Atorvastatin Calcium | 548 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 515 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 106 |
| Eliquis | Apixaban | 289 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 255 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 64 |
| Gabapentin | Gabapentin | 236 | 64 |
| Furosemide | Furosemide | 221 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 62 |
| Losartan Potassium | Losartan Potassium | 191 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 39 |
| Carvedilol | Carvedilol | 172 | 41 |
| Omeprazole | Omeprazole | 167 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 43 |
| Allopurinol | Allopurinol | 150 | 37 |
| Metformin Hcl | Metformin Hcl | 143 | 44 |
| Celecoxib | Celecoxib | 130 | 36 |
| Simvastatin | Simvastatin | 128 | 32 |
| Atenolol | Atenolol | 125 | 30 |
| Famotidine | Famotidine | 125 | 34 |
| Lisinopril | Lisinopril | 124 | 38 |
| Montelukast Sodium | Montelukast Sodium | 121 | 30 |
| Ezetimibe | Ezetimibe | 119 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 117 | 42 |
| Sertraline Hcl | Sertraline Hcl | 105 | 28 |
| Irbesartan | Irbesartan | 103 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 27 |
| Baclofen | Baclofen | 98 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 29 |
| Tramadol Hcl | Tramadol Hcl | 98 | 33 |
| Trazodone Hcl | Trazodone Hcl | 98 | 27 |
| Dexamethasone | Dexamethasone | 94 | 67 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 21 |
| Clonazepam | Clonazepam | 79 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 15 |
| Jardiance | Empagliflozin | 77 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 19 |
| Finasteride | Finasteride | 72 | 18 |
| Bupropion Xl | Bupropion Hcl | 71 | 19 |
| Meclizine Hcl | Meclizine Hcl | 70 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 14 |
| Valsartan | Valsartan | 69 | 21 |
| Lorazepam | Lorazepam | 67 | 23 |
| Potassium Chloride | Potassium Chloride | 67 | 24 |
| Repaglinide | Repaglinide | 67 | 13 |
| Topiramate | Topiramate | 67 | 19 |
| Warfarin Sodium | Warfarin Sodium | 64 | 13 |
| Synthroid | Levothyroxine Sodium | 61 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 16 |
| Alprazolam | Alprazolam | 59 | 32 |
| Trulicity | Dulaglutide | 58 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 14 |
| Ozempic | Semaglutide | 57 | suppressed |
| Meloxicam | Meloxicam | 55 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 53 | 39 |
| Donepezil Hcl | Donepezil Hcl | 52 | 16 |
| Entresto | Sacubitril/Valsartan | 51 | 14 |
| Xarelto | Rivaroxaban | 51 | 11 |
| Spironolactone | Spironolactone | 46 | 14 |
| Prednisone | Prednisone | 45 | 34 |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 17 |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 38 | 38 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 15 |
| Torsemide | Torsemide | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 14 |
| Folic Acid | Folic Acid | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 32 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 20 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 19 |
| Sotalol | Sotalol Hcl | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 23 |
| Colchicine | Colchicine | 24 | 13 |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.41 · 6 records | Edwards Lifesciences Corporation | AIRSUPRA, QULIPTA, SAPIEN 3 Ultra RESILIA, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error